Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer

NCT05548296 is registered in ClinicalTrials.gov with Acrivon Therapeutics as lead sponsor.

NCT NCT05548296
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05548296 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of ACR-368 Therapy in Subjects With Endometrial Cancer
Lead sponsor
Acrivon Therapeutics
Phase
Phase 2
Overall status
Recruiting
Start date
August 29, 2022
Completion date
November 30, 2027
Enrollment
350 (estimated)
Sites
90

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma